Segment, Geographic and Other Revenue Information (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Revenues	[1]	$ 11,801	$ 13,264	$ 23,829	$ 26,382
Earnings	[1],[2]	3,953	4,141	7,838	8,463
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		11,801	12,402	23,829	24,661
Earnings	[2]	7,818	8,044	15,738	16,206
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues		0	862	0	1,721
Earnings	[2]	(1,530)	(1,193)	(3,019)	(2,306)
Segment Reconciling Items [Member] | Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Revenues		0	0	0	0
Earnings	[2]	(910)	(1,178)	(1,722)	(2,217)
Segment Reconciling Items [Member] | Acquisition-Related Costs [Member]
Segment Reporting Information [Line Items]
Revenues		0	0	0	0
Earnings	[2]	(21)	176	(34)	148
Segment Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Revenues	[3]	0	0	0	0
Earnings	[2],[3]	(268)	(309)	(879)	(691)
Corporate and other unallocated [Member]
Segment Reporting Information [Line Items]
Revenues		0	0	0	0
Earnings	[2]	(1,136)	(1,399)	(2,245)	(2,676)
Biopharma [Member]
Segment Reporting Information [Line Items]
Revenues		9,795	9,432	19,802	18,477
Biopharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		9,795	9,432	19,802	18,477
Earnings	[2]	6,650	6,071	13,379	11,954
Upjohn [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		2,006	2,970	4,027	6,184
Earnings	[2]	$ 1,168	$ 1,973	$ 2,359	$ 4,251

[1] Amounts may not add due to rounding.

[2] Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income of $76 million in the second quarter of 2020 and $76 million in the second quarter of 2019, and $153 million in the first six months of 2020 and $140 million in the first six months of 2019 from our investment in ViiV. For additional information, see Note 4.

[3] Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.